Search

Displaying results 3741 - 3750 of 8974 in total
  1. Drug

    Lorazepam

    go.drugbank.com/drugs/DB00186
    ApprovedInvestigational

    [A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. … The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.[L5095]

    Synonyms: o-Chloroxazepam, o-Chlorooxazepam
  2. Drug

    Vusolimogene oderparepvec

    go.drugbank.com/drugs/DB23008
    ApprovedInvestigational

    [L64061] It is administered by direct injection into superficial, deep, or visceral tumors. … [L64061,L64062] It is the second oncolytic viral therapy approved in the United States, following talimogene laherparepvec (T-VEC, Imlygic) in 2015, and the first approved for melanoma that has progressed

  3. Drug

    Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10799
    ApprovedInvestigational

    Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria … The vaccine contains *N. meningitis* serogroup c capsular polysaccharide antigens that are purified and individually conjugated to diphtheria toxoid protein that are extracted from Corynebacterium diphtheriae

  4. Drug

    Neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10800
    ApprovedInvestigational

    Neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria … The vaccine contains* N. meningitis* serogroup y capsular polysaccharide antigens that are purified and individually conjugated to diphtheria toxoid protein that are extracted from Corynebacterium diphtheriae

  5. Drug

    Acipimox

    go.drugbank.com/drugs/DB09055
    ApprovedInvestigational

    Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. … Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use.

  6. Drug

    Topiroxostat

    go.drugbank.com/drugs/DB01685
    Investigational

    Topiroxostat and its metabolites are shown to be unaffected by renal complications, thus may be effective in patients with chronic kidney diseases [A19657]. … Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout.

  7. Drug

    Droxidopa

    go.drugbank.com/drugs/DB06262
    ApprovedInvestigational

    It is approved for use in Japan and is currently in trials in the U.S. … Chelsea Therapeutics obtained orphan drug status (ODS) for L-DOPS in the U.S. for NOH, and that of which associated with Parkinson's disease , pure autonomic failure, and multiple system atrophy, and is

  8. Drug

    Amcinonide

    go.drugbank.com/drugs/DB00288
    Approved

    Amcinonide is a corticosteroid.

  9. Drug

    Dioxybenzone

    go.drugbank.com/drugs/DB11221
    ApprovedWithdrawn

    Dioxybenzone is an approved sunscreen ingredient in concentrations up to 3% [L2525]. … Dioxybenzone, or benzophenone-8, is an organic compound derived from [DB01878] that is used as a sunscreen agent. It absorbed UV-B and UV-AII rays.

  10. Drug

    Zongertinib

    go.drugbank.com/drugs/DB18762
    ApprovedInvestigational

    [L53873,A274363] On August 8, 2025, the US FDA granted accelerated approval to zongertinib for the treatment of advanced forms of non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain … serves to limit associated toxicities.